Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib extension study to evaluate IkT-148009 in Parkinson's patients

Next Previous
X
Search
Trial Profile

A Phase Ib extension study to evaluate IkT-148009 in Parkinson's patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risvodetinib (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Inhibikase Therapeutics

    • Most Recent Events

    • 06 Apr 2022 According to an Inhibikase Therapeutics media release, the company will host a virtual KOL investor event. Presentations will highlight recently presented Phase 1 and Phase 1b data for IkT-148009 for the treatment of Parkinson's disease.
    • 31 Mar 2022 According to an Inhibikase Therapeutics media release, the company expects to complete dosing of the Phase 1b study in the second quarter of 2022 and present full data at a medical meeting later this year.
    • 05 Jan 2022 According to a Inhibikase Therapeutics media release, Inhibikase expects to complete enrollment and analysis of the first two cohorts of 8 patients with mild to moderate Parkinson's disease in the first quarter of 2022, with the third cohort completed in the second quarter of 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top